Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, double-dummy, placebo-controlled,
single-dose, 5-treatment, 5-period, 5-way crossover study in pediatric patients with
persistent asthma. The primary purpose of this study is to compare the efficacy and safety of
Albuterol Spiromax with that of ProAir HFA in pediatric asthma patients at 2 delivered dose
levels equivalent to 90 mcg and 180 mcg of albuterol base.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.